BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATIONBusiness Wire • 09/09/26
Bayer Aktiengesellschaft (BAYRY) Discusses Innovation Strategy and Progress on Five-Year Growth Framework in Crop Science Division TranscriptSeeking Alpha • 09/03/26
Bayer Advances Combined Seed and Crop Protection Pipeline and Enters Phase of Blockbuster LaunchesBusiness Wire • 09/02/26
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakersCNBC • 08/31/26
Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026Business Wire • 08/20/26
Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in USReuters • 07/30/26
New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems MattersBusiness Wire • 07/23/26
Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical TrialsBusiness Wire • 07/17/26